deferoxamine has been researched along with digoxin in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (12.50) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Fujibayashi, Y; Iijima, N; Konishi, J; Takemura, Y; Taniuchi, H; Yokoyama, A | 1 |
| CAHILL, M | 1 |
| Khan, SA; Luo, W; Nanduri, J; Prabhakar, NR; Semenza, GL; Yuan, G | 1 |
| Chiang, TK; Kurup, SK; White, KM; Yu, M | 1 |
2 review(s) available for deferoxamine and digoxin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Use of Visual Electrophysiology to Monitor Retinal and Optic Nerve Toxicity.
Topics: Amiodarone; Cefuroxime; Chlorpromazine; Cisplatin; Deferoxamine; Digoxin; Electrophysiology; Ethambutol; Evoked Potentials, Visual; Humans; Hydroxychloroquine; Isotretinoin; Optic Nerve; Phosphodiesterase 5 Inhibitors; Quinine; Retina; Tamoxifen; Thioridazine; Topiramate; Vigabatrin | 2022 |
6 other study(ies) available for deferoxamine and digoxin
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Basic evaluation of 67Ga labeled digoxin derivative as a metal-labeled bifunctional radiopharmaceutical.
Topics: Cross-Linking Reagents; Deferoxamine; Digoxin; Evaluation Studies as Topic; Gallium Radioisotopes; Radioactive Tracers | 1993 |
HAEMOCHROMATOSIS, A BLOOD DYSCRASIA.
Topics: Clinical Laboratory Techniques; Deferoxamine; Diet; Diet, Reducing; Digoxin; Drug Therapy; Hematologic Diseases; Hemochromatosis; Outpatient Clinics, Hospital; Physical Examination; Vascular Diseases | 1964 |
Hypoxia-inducible factor 1 mediates increased expression of NADPH oxidase-2 in response to intermittent hypoxia.
Topics: Animals; Carotid Body; Central Nervous System; Deferoxamine; Digoxin; Enzyme Inhibitors; Fibroblasts; Furans; Gene Expression Regulation; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Indazoles; Male; Membrane Glycoproteins; Mice; Mice, Inbred BALB C; NADPH Oxidase 2; NADPH Oxidases; PC12 Cells; Peripheral Nervous System; Rats; Reactive Oxygen Species; Siderophores; Sleep Apnea Syndromes | 2011 |